Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Retz

Showing results (41-50 of 84) with videos related to

Pageof 9
Sort By:
Der Urologe. Ausg. A|October 15, 2013
[Systemic therapy of metastatic bladder cancer.]M Retz, S C Schmid, M W Kramer, et al.
Der Urologe. Ausg. A|August 13, 2008
[German Association for Bladder Cancer Research]M Retz, A Hartmann, A Merseburger, et al.
The Journal of Urology|December 13, 2002
Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumorM Retz, J Lehmann, E Amann, et al.
Der Urologe. Ausg. A|November 20, 2015
[Inguinal lymphadenectomy in penile cancer: Study for prevention of wound complications after inguinal lymphadenectomy in patients with penile cancer by epidermal vacuum therapy (PräVAC, EUDAMED: CIV-12-07-008204; DRKS-ID: DRKS00005257)]T Maurer, A K Seitz, S Schneider, et al.
European Urology|September 6, 2005
New HIV-drug inhibits in vitro bladder cancer migration and invasionM Retz, S S Sidhu, J Lehmann, et al.
Der Urologe. Ausg. A|November 26, 2016
[PSMA-targeted radioligand therapy in prostate cancer]M M Heck, M Retz, R Tauber, et al.
Oncogene|June 2, 2010
EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesisS S Sidhu, R Nawroth, M Retz, et al.
Der Urologe. Ausg. A|February 15, 2012
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients]M M Heck, M Höppner, T Horn, et al.
Der Pathologe|July 28, 2010
[EMMPRIN (CD147). A prognostic and potentially therapeutic marker in urothelial cancer]R Nawroth, A Hartmann, P Wild, et al.
Urologie (Heidelberg, Germany)|August 4, 2022
[Quality assurance for the treatment of muscle-invasive and metastasized bladder carcinoma in Germany : An initiative of the Working Groups Urological Oncology (AUO) and Internal Oncology (AIO) in the German Cancer Society (DKG)]C H Ohlmann, M Kerkmann, L Holtmann, et al.
Pageof 9

Showing results (41-50 of 84) with videos related to

Sort By:
Pageof 9
Der Urologe. Ausg. A|October 15, 2013
[Systemic therapy of metastatic bladder cancer.]M Retz, S C Schmid, M W Kramer, et al.
Der Urologe. Ausg. A|August 13, 2008
[German Association for Bladder Cancer Research]M Retz, A Hartmann, A Merseburger, et al.
The Journal of Urology|December 13, 2002
Mucin 7 and cytokeratin 20 as new diagnostic urinary markers for bladder tumorM Retz, J Lehmann, E Amann, et al.
Der Urologe. Ausg. A|November 20, 2015
[Inguinal lymphadenectomy in penile cancer: Study for prevention of wound complications after inguinal lymphadenectomy in patients with penile cancer by epidermal vacuum therapy (PräVAC, EUDAMED: CIV-12-07-008204; DRKS-ID: DRKS00005257)]T Maurer, A K Seitz, S Schneider, et al.
European Urology|September 6, 2005
New HIV-drug inhibits in vitro bladder cancer migration and invasionM Retz, S S Sidhu, J Lehmann, et al.
Der Urologe. Ausg. A|November 26, 2016
[PSMA-targeted radioligand therapy in prostate cancer]M M Heck, M Retz, R Tauber, et al.
Oncogene|June 2, 2010
EMMPRIN regulates the canonical Wnt/beta-catenin signaling pathway, a potential role in accelerating lung tumorigenesisS S Sidhu, R Nawroth, M Retz, et al.
Der Urologe. Ausg. A|February 15, 2012
[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients]M M Heck, M Höppner, T Horn, et al.
Der Pathologe|July 28, 2010
[EMMPRIN (CD147). A prognostic and potentially therapeutic marker in urothelial cancer]R Nawroth, A Hartmann, P Wild, et al.
Urologie (Heidelberg, Germany)|August 4, 2022
[Quality assurance for the treatment of muscle-invasive and metastasized bladder carcinoma in Germany : An initiative of the Working Groups Urological Oncology (AUO) and Internal Oncology (AIO) in the German Cancer Society (DKG)]C H Ohlmann, M Kerkmann, L Holtmann, et al.
Pageof 9